Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 14, 2013, Pages 1841-1848

  Ratzer, R ^a   Sondergaard H B ^a   Christensen, J Romme ^a   Bornsen L ^a   Borup, R ^a   Sorensen P S ^a   Sellebjerg, F ^a  

^a Rigshospitalet   (Denmark)

Author keywords

gene expression; immunology; microarray; Multiple sclerosis; pathway analysis; progressive multiple sclerosis

Indexed keywords

ADAPTIVE IMMUNITY; ADULT; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; SIGNAL TRANSDUCTION;

GENE EXPRESSION; IMMUNOLOGY; MICROARRAY; MULTIPLE SCLEROSIS; PATHWAY ANALYSIS; PROGRESSIVE MULTIPLE SCLEROSIS;

FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84888617781     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513500553     Document Type: Article

References (35)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 ; 372: 1502-1517
2. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
3. Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012 ; 135: 2925-2937
4. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009 ; 132: 1175-1189
5. Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010 ; 68: 477-493
6. Achiron A, Gurevich M, Friedman N, et al. Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity. Ann Neurol. 2004 ; 55: 410-417
7. Gandhi KS, McKay FC, Cox M, et al. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet. 2010 ; 19: 2134-2143
8. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002 ; 8: 500-508
9. Ramanathan M, Weinstock-Guttman B, Nguyen LT, et al. In vivo gene expression revealed by cDNA arrays: The pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J Neuroimmunol. 2001 ; 116: 213-219
10. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
11. Wei C, Li J, Bumgarner RE. Sample size for detecting differentially expressedgenes in microarray experiments. BMC Genomics. 2004 ; 5: 87
12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B. 1995 ; 57: 289-300
13. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology. 2005 ; 64: 1144-1151
14. Bomprezzi R, Ringner M, Kim S, et al. Gene expression profile in multiple sclerosis patients and healthy controls: Identifying pathways relevant to disease. Hum Mol Genet. 2003 ; 12: 2191-2199
15. Fossey SC, Vnencak-Jones CL, Olsen NJ, et al. Identification of molecular biomarkers for multiple sclerosis. J Mol Diagn. 2007 ; 9: 197-204
16. Kemppinen AK, Kaprio J, Palotie A, et al. Systematic review of genome-wide expression studies in multiple sclerosis. BMJ Open. 2011 ; 1: e000053
17. Brynedal B, Khademi M, Wallstrom E, et al. Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery?. Neurobiol Dis. 2010 ; 37: 613-621
18. Gurevich M, Tuller T, Rubinstein U, et al. Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med Genomics. 2009 ; 2: 46
19. Ottoboni L, Keenan BT, Tamayo P, et al. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 ; 4: 153ra131
20. Satoh J, Nakanishi M, Koike F, et al. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. J Neuroimmunol. 2006 ; 174: 108-118
21. Satoh J, Misawa T, Tabunoki H, et al. Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-kappaB as a biomarker for relapse of multiple sclerosis. Dis Markers. 2008 ; 25: 27-35
22. Arthur AT, Armati PJ, Bye C, et al. Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Med Genet. 2008 ; 9: 17
23. Hesse D, Krakauer M, Lund H, et al. Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis?. Eur J Neurol. 2011 ; 18: 266-272
24. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun. 2006 ; 7: 522-531
25. Yamaguchi KD, Ruderman DL, Croze E, et al. IFN-beta-regulated genes show abnormal expression in therapy-naive relapsing-remitting MS mononuclear cells: Gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol. 2008 ; 195: 116-120
26. Christensen JR, Börnsen L, Ratzer R, et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One. 2013 ; 8: e57820
27. Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol. 2009 ; 66: 132-141
28. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688
29. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 ; 66: 460-471
30. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011 ; 378: 1779-1787
31. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann Neurol. 2010 ; 67: 452-461
32. Weiner HL. A shift from adaptive to innate immunity: A potential mechanism of disease progression in multiple sclerosis. J Neurol. 2008 ; 255: 3-11
33. Iglesias AH, Camelo S, Hwang D, et al. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J Neuroimmunol. 2004 ; 150: 163-177
34. Mayne M, Moffatt T, Kong H, et al. CYFIP2 is highly abundant in CD4+ cells from multiple sclerosis patients and is involved in T cell adhesion. Eur J Immunol. 2004 ; 34: 1217-1227
35. Riveros C, Mellor D, Gandhi KS, et al. A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis. PLoS One. 2010 ; 5: e14176